Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Portuguese Journal of Dermatology and Venereology
Print version ISSN 2795-501XOn-line version ISSN 2795-5001
Abstract
REIS, Joel; RAPOSO, Inês and SELORES, Manuela. Dupilumab for recalcitrant prurigo nodularis: Case report. Port J Dermatol Venereol. [online]. 2022, vol.80, n.1, pp.56-59. Epub May 16, 2022. ISSN 2795-501X. https://doi.org/10.24875/pjd.m22000010.
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.
Keywords : Antibodies; Monoclonal; Humanized; Dupilumab; Prurigo/drug therapy.